Delayed hypotensive effect of the thromboxane A2/prostaglandin H2 receptor antagonist S-1452 in spontaneously hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 8, 2000, Pages 594-600

  Sugimoto, Koh Ichi ^a   Shiga, Tsuyoshi ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Antagonist; Blood pressure; Hypertension; Spontaneously hypertensive rat; Thromboxane A2

Indexed keywords

DOMITROBAN; IFETROBAN; PROSTAGLANDIN H2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; THROMBOXANE A2 RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; HYPERTENSION; HYPOTENSION; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOCYTE AGGREGATION; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

6-KETOPROSTAGLANDIN F1 ALPHA; ALDOSTERONE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BICYCLO COMPOUNDS; BLOOD PRESSURE; DINOPROSTONE; FATTY ACIDS, MONOUNSATURATED; HYPERTENSION; MALE; POTASSIUM; PROSTAGLANDIN ANTAGONISTS; PROSTAGLANDINS; PROSTAGLANDINS H; PROTEINURIA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, PROSTAGLANDIN; RECEPTORS, THROMBOXANE; RENIN; SODIUM; THROMBOXANE B2; TIME FACTORS;

EID: 0033949310     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03307.x     Document Type: Article

References (30)

1. 1. Abe K, Yasujima M, Chiba S, Irokawa N, Ito T, Yoshinaga K. Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension. Prostaglandins 1977; 14: 513-21.
2. 2: A newly identified lesion in human essential hypertension. Prostaglandins 1978; 15: 139-49.
3. 3. Weber PC, Scherer B, Held E, Siess W, Stoffel H. Urinary prostaglandins and kallikrein in essential hypertension. Clin. Sci. 1979; 57: S259-61.
4. 2 in borderline and essential hypertensive patients. Prostagland. Leukot. Med. 1983; 10: 145-55.
5. 2 biosynthesis in the kidney of spontaneously hypertensive rats during development of hypertension. Eur J. Pharmacol. 1981; 70: 247-56.
6. 6. Soma M, Manku MS, Jenkins DK, Horrobin DF. Prostaglandins and thromboxane outflow from the perfused mesenteric vascular bed in spontaneously hypertensive rats. Prostaglandins 1985; 29: 323-33.
7. 2 in spontaneously hypertensive rats. J. Hypertens. 1987; 5: 299-304.
8. 8. Ishimitsu T, Uehara Y, Ishii M, Ikeda T, Matsuoka H, Sugimoto T. Thromboxane and vascular smooth muscle cell growth in genetically hypertensive rats. Hypertension 1988; 12: 46-51.
9. 9. Ishimitsu T, Uehara Y, Ishii M, Ikeda T, Matsuoka H, Sugimoto T. Alterations of the cerebrovascular and renal prostaglandins and thromboxanes system in prehypertensive spontaneously hypertensive rats. Jpn. Circ. J. 1989; 53: 307-12.
10. 10. Chatziantoniou C, Daniels FH, Arendshorst WJ. Exaggerated renal vascular reactivity to angiotensin and thromboxane in young genetically hypertensive rats. Am. J. Physiol. 1990; 259: F372-82.
11. 11. Gomi T, Ikeda T, Ishimitsu T, Uehara Y. Effects of OKY-046, a selective thromboxane synthetase inhibitor, on blood pressure and thromboxane synthesis in spontaneously hypertensive rats. Prostagland. Leukot, Essent. Fatty Acids 1989; 37: 139-44.
12. 2 synthase inhibitor. Eur. J. Pharmacol. 1985; 109: 135-44.
13. 13. Iwama Y, Kato T, Muramatsu M et al. Correlation with blood pressure of the acetylcholine-induced endothelium-derived contracting factor in the rat aorta. Hypertension 1992; 19: 326-32.
14. 14. Tesfamariam B, Ogletree ML. Dissociation of endothelial cell dysfunction and blood pressure in SHR. Am. J. Physiol. 1995; 269: H189-94.
15. 2 blockade in spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 1993; 20: 679-87.
16. 2 receptor antagonist, in strokeprone spontaneously hypertensive rats. Clin. Exp. Hypertens. 1996; 18: 171-81.
17. 2 receptor antagonist. Cardiovasc. Drug Rev. 1992; 10: 280-95.
18. 18. Liu KL, Hadj Aissa A, Laréal MC, Benzoni D, Vincent M, Sassard J. Adrenergic stimulation of renal prostanoids in the Lyon hypertensive rat. Hypertension 1991; 17: 296-302.
19. 2/PGH; receptor activation in rats. Am. J. Physiol. 1997; 273: H734-9.
20. 20. Wilcox CS, Welch WJ. Thromboxane mediation of the pressor response to infused angiotensin II. Am. J. Hypertens. 1990; 3: 242-9.
21. 2 receptor in the vasoconstrictor response of rat aorta to endothelin. J. Pharmacol. Exp. Ther. 1990; 252: 915-21.
22. 22. Lee S-L, Levitsky S, Feinberg H. Endogenous vasoconstrictor prostanoids: Role in derotonin and vasopressin-induced coronary vasoconstriction. J. Pharmacol Exp. Ther. 1991; 258: 292-8.
23. 23. Purkerson ML, Martin KJ, Yates J, Kissane JM, Klahr S. Thromboxane synthesis and blood pressure in spontaneously hypertensive rats. Hypertension 1986; 8: 1113-20.
24. 24. Mistry M, Nasjletti A. Contrasting effect of thromboxane synthase inhibitor antagonist on the development of angiotensin II-salt-induced hypertension in rats. J. Pharmacol. Exp. Ther. 1990; 253: 90-4.
25. 25. Lin L, Misry M, Stier CT, Nasjletti A. Role of prostanoids in renindependent and renin-independent hypertension. Hypertension 1991; 17: 517-25.
26. 2 receptors maintain hypertension throughout 2K, 1C Goldblatt hypertension in the rat. Am. J. Physiol. 1996; 271: R891-6.
27. 2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 1990; 15: 699-703.
28. 28. Huang A, Sun D, Koller A. Endothelial dysfunction augments myogenic arteriolar constriction in hypertension. Hypertension 1993; 22: 913-21.
29. 29. Lang MG, Noll G, Lüscher TF. Effect of aging and hypertension on contractility on resistance arteries: Modulation by endothelial factors. Am. J. Physiol. 1995; 269: H837-44.
30. 30. Quest DW, Wilson TW. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat. Jpn. J. Pharmacol. 1998; 78: 479-86.